Previous 10 | Next 10 |
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Gainers: Avadel Pharmaceuticals AVDL +61%. PMV Pharmaceuticals PMVP +25%. Alpha Tau Medical (DRTS) +18%. SIGA Technologies SIGA +18%. Allarity Therapeutics (ALLR) +17%. Losers: Iovance Biotherapeutics (IOVA) -54%. SpringWorks Therapeutics SWTX...
Avadel Pharmaceuticals (AVDL) +39%. Solo Brands (DTC) +14%. PMV Pharmaceuticals (PMVP) +15% on early data for lead asset in solid tumors. Red Robin Gourmet Burgers (RRGB) +13% on Q1 earnings release. DiDi Global (DIDI) +11% on report of China's FAW interest ...
PMV Pharmaceuticals (NASDAQ:PMVP) has added ~13% in the pre-market Friday after the precision oncology company shared data from an ongoing Phase 1/2 for its lead program PC14586 in patients with advanced solid tumors that have a p53 Y220C mutation. PC14586 is an experimental small m...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips NewAge (NASDAQ: NBEV ) leads our gainers today. Iovance Biotherapeutics (NASDAQ: IOVA ) tops our losers. Several retail stocks are slipping on earnings reports today. Source: ventdusud / Shutterstock.c...
Gainers: Adicet (ACET) +25%. PMV Pharmaceuticals (PMVP) +20%. Red Robin Gourmet Burgers (RRGB) +18%. Aesthetic Medical International Holdings Group (AIH) +13%. Elevation Oncology (ELEV) +9%. Losers: Iovance Biotherapeutics (IOVA) -50%. Aurora Cannabis (ACB) -18%. M...
Preliminary results represent the first clinical evidence of targeting a p53 Y220C mutation ASCO abstract highlights 3/10 (30%) partial responses in patients treated in higher dose cohorts and activity observed in multiple tumor types Updated data from ongoing Ph...
Gainers: Elevation Oncology (ELEV) +20%. Cue Biopharma (CUE) +14%. Evelo Biosciences (EVLO) +13%. GeoVax Labs (GOVX) +13%. Immix Biopharma (IMMX) +9%. Losers: Verrica Pharmaceuticals (VRCA) -58%. PMV Pharmaceuticals (PMVP) -10%. TransMedics (TMDX) ...
PMV Pharmaceuticals press release (NASDAQ:PMVP): Q1 GAAP EPS of -$0.41 beats by $0.01. As of March 31, 2022, PMV Pharma had $294.8 million in cash, cash equivalents, and marketable securities, compared to $314.1 million as of December 31, 2021. Net cash used in operat...
Oral presentation at 2022 ASCO annual meeting to highlight initial data from ongoing Phase 1/2 PYNNACLE study of PC14586 in patients with advanced solid tumors CRANBURY, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology ...
News, Short Squeeze, Breakout and More Instantly...
PMV Pharmaceuticals Inc. Company Name:
PMVP Stock Symbol:
NASDAQ Market:
PMV Pharmaceuticals Inc. Website:
PRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Off...
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOn...
2024-05-13 08:30:02 ET Craig-Hallum analyst issues BUY recommendation for PMVP on May 13, 2024 07:30AM ET. PMVP was trading at $2.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy recommendations...